Last reviewed · How we verify

Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoTM Alprazolam for Inhalation in Normal, Healthy Volunteers

NCT00444522 Phase 1 COMPLETED

We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.

Details

Lead sponsorAlexza Pharmaceuticals, Inc.
PhasePhase 1
StatusCOMPLETED
Enrolment50
Start date2005-06
Completion2005-08

Conditions

Interventions

Primary outcomes